Pharma rivals are fighting Covid together. Why stop there? | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Friday
September 22, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
FRIDAY, SEPTEMBER 22, 2023
Pharma rivals are fighting Covid together. Why stop there?

Panorama

Max Nisen, Bloomberg
26 August, 2020, 01:30 pm
Last modified: 26 August, 2020, 03:24 pm

Related News

  • Covid-19 economic impact lingers on in parts of society: Study
  • Jill Biden positive for Covid, President Biden tests negative: White House
  • China will not require Covid-19 testing for incoming travelers
  • Global Covid-19 incidence up by over 60% in 28 days: WHO
  • Pandemic, inflation push 68 million more in Asia into extreme poverty: ADB

Pharma rivals are fighting Covid together. Why stop there?

Some of the world’s biggest drugmakers are making unusual deals to get more medicine to more people at a lower cost. Not a bad idea

Max Nisen, Bloomberg
26 August, 2020, 01:30 pm
Last modified: 26 August, 2020, 03:24 pm
The urgent need for effective Covid-19 treatments and vaccines is causing a shift in drugmakers’ priorities. Photographer:  Andrey Rudakov/Bloomberg
The urgent need for effective Covid-19 treatments and vaccines is causing a shift in drugmakers’ priorities. Photographer: Andrey Rudakov/Bloomberg

Pandemics make for strange bedfellows and behavior in the pharmaceutical industry.

The world is relying on drugmakers' expertise to get us out of the Covid-19 crisis — initially with treatments to help lessen the risks from contracting the virus, and then ultimately with a vaccine. The high pressure, enormous need, and global attention are leading companies to try new things on the fly. Just last week, Regeneron Pharmaceuticals Inc. signed a pact with its erstwhile rival Roche Holding AG aimed at substantially boosting supplies of a potential treatment for Covid-19; it even made some monetary sacrifices to do so. And that's only the latest example. 

Much of what's happening represents a war-time type response to a unique situation, and it may not be repeated. These are for-profit companies, after all, and they will act accordingly. But from an unprecedented vaccine hunt to international manufacturing deals, the drug industry's response shows the possibilities of what a more collaborative medicine market could bring.  

Take the Regeneron-Roche deal, under which Regeneron will sell its promising antibody therapy in the US, and Roche will handle the rest of the world. The companies will carry their own manufacturing and distribution costs and divide development expenses and profit. Roche's muscle could more than triple capacity, according to Regeneron. 

Typically, Roche would pay a hefty price for a cut of a promising drug's potential sales. In this case, Regeneron is forgoing that customary upfront payment and surety in favor of maximizing supply during the pandemic. Regeneron won't be able to satisfy global demand on its own, and Roche is a giant in the field of antibody drugs. The bigger company has a lot of incentive to scale up manufacturing; it will receive between 40% and 50% of gross profit.

Regeneron will get nothing but some of its costs covered if it doesn't pan out. However, the company can't sell medicine that it can't make. Picking volume and patient access over a higher profit margin — a tactic drugmakers too rarely embrace — makes sense from a humanitarian and business perspective.

While the Regeneron-Roche deal focuses on antibody manufacturing, uncommon partnerships and arrangements are forming in other areas as well to meet various pressing needs. Here are just a few:

  • Ensuring worldwide supply: Gilead Sciences Inc., the company behind remdesivir —  one of the few Covid treatments available — freely gave away a license so that several generic drugmakers can make a low-cost version for developing countries, something that generally doesn't happen for a brand-new medicine and will dramatically boost the drug's availability.
  • Collaborating on a vaccine: Fierce competitors Sanofi and GlaxoSmithKline PLC formed a historic partnership under which one will provide the core of a vaccine, and the second a type of booster called an adjuvant. 
  • Pricing for access: Instead of leaving prices to the free market as it often does, the US is behaving like other countries that manage to keep drug costs at a reasonable level by negotiating the price of hundreds of millions of doses of vaccine before they reach the market. It's been helped by non-profit pledges from AstraZeneca PLC and Johnson & Johnson, who are developing two leading candidates.  However, the prices negotiated with companies that aim to make a  profit are lower than the private-market norm for new shots. Uncle Sam is buying the doses and the first wave of vaccines will be free for Americans. It's a sharp contrast to ordinary times, where the world's highest drug prices lead to financial hardship and skipped treatments. 
  • Risk-sharing:  At least one of the US government's Operation Warp Speed vaccine deals includes risk-sharing structures I've never seen in a government contract. The US will pay less for Moderna Therapeutic Inc's vaccine if the company is slow to deliver it. The company also has an opportunity to get a $600 million chunk of money early if it can meet ambitious manufacturing timelines.
  • Fixing a broken market: Infectious disease research, the neglected and unprofitable stepchild of drug development, is being lavished with money and attention. The US alone has committed or promised over $10 billion to six companies and many more are working on novel vaccines. Hopefully, the large sums will convince companies to continue to invest.  

It's great that companies and the government are stepping up. But the moment will be wasted if everything snaps back post-pandemic. Better pricing, more focus on patients and public health, and less duplication of effort are all possible and should be the expectation even when there isn't a crisis. 


Disclaimer: This article first appeared on Bloomberg, and is published by special syndication arrangement

Analysis / Top News

pharmaceutical companies / fighting coronavirus / COVID-19 / Pharmaceutical Industry / Drug makers / Coronavirus / covid-19 vaccine / Covid-19 vaccines / Covid-19 treatment / Coronavirus treatment

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Will 10 crore eggs make any difference?
    Will 10 crore eggs make any difference?
  • The bridge at Dhanmondi 8 has been submerged in the rainwater on Thursday (21 September). Photo: TBS
    4 die from electrocution as live wire falls in rainwater in Mirpur
  • Rain water entered in many roadside shops in the city. This photo was taken from a shop in Zafrabad, West Dhanmondi on Thursday (21 September). Photo: TBS
    Heavy rain causes severe waterlogging in Dhaka

Related News

  • Covid-19 economic impact lingers on in parts of society: Study
  • Jill Biden positive for Covid, President Biden tests negative: White House
  • China will not require Covid-19 testing for incoming travelers
  • Global Covid-19 incidence up by over 60% in 28 days: WHO
  • Pandemic, inflation push 68 million more in Asia into extreme poverty: ADB

Features

Mountain gorillas are vulnerable species, only found in the willderness. Photo: Muntasir Akash

Against all odds: My encounters with mountain gorillas in Rwanda

10h | Earth
Photo: Saqlain Rizve

The quiet afterglow of Dhaka's overhead water tanks

16h | Panorama
Photo: Shovy Zibran

Maachh-bhaat for the soul: How Mariam nourishes hearts on the streets of Dhaka

1d | Panorama
Team Bored Tunnelers is a cross-institutional team consisting of six board members: (from let to right) Talha Zubair, Shaekh Mohammad Shithil, Fahin Uddin, Imran Khan, Shahriar Iqbal Mahim and Sibly Noman. Photo: Courtesy

Meet the Bangladesh team in Elon Musk's Not-a-Boring Competition finals

1d | Pursuit

More Videos from TBS

After almost two months, the Ukrainian grain ship left the Black Sea port

After almost two months, the Ukrainian grain ship left the Black Sea port

5h | TBS World
Revenue collection rises 15% in first two months of FY24

Revenue collection rises 15% in first two months of FY24

2h | TBS Economy
Fans call for Amir’s inclusion after Naseem Shah's injury

Fans call for Amir’s inclusion after Naseem Shah's injury

3h | TBS SPORTS
The need for a circular economy in Bangladesh

The need for a circular economy in Bangladesh

6h | TBS Face to Face
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]